TSHA insider files Form 144 to sell 200,000 shares

Taysha Gene Therapies filed a Form 144 reporting a proposed sale of 200,000 shares by Sukumar Nagendran.

Rhea-AI Filing Summary

Taysha Gene Therapies filed a Form 144 reporting a proposed sale of 200,000 shares by Sukumar Nagendran. The filing lists a sale date of 01/12/2026 and a gross amount of $942,740 tied to those shares. The disclosure also lists prior grants: 131,550 RSUs, 49,429 RSUs, and 19,021 stock options with grant dates shown in 2024 and 2025.

Insights

Insider Transactions Specialist

Routine Form 144 sale report showing an insider proposed sale of 200,000 shares.

The filing records a proposed disposition of 200,000 shares by Sukumar Nagendran and lists a gross dollar amount of $942,740 associated with that quantity. This is a standard disclosure of an insider sale method required by securities rules.

Timing and settlement specifics beyond the listed date 01/12/2026 are not included in the excerpt; subsequent filings or broker reports would show completion details.

Key Figures

Proposed sale: 200,000 shares Gross amount listed: $942,740 RSU grant (2024): 131,550 RSUs +2 more

5 metrics

Proposed sale 200,000 shares sale dated 01/12/2026

Gross amount listed $942,740 tied to the 200,000 shares

RSU grant (2024) 131,550 RSUs grant date 01/02/2024

RSU grant (2025) 49,429 RSUs grant date 01/02/2025

Stock option grant 19,021 options grant date 01/02/2024

Key Terms

Form 144, RSU, Stock Option Grant

3 terms

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSU financial

"01/02/2024 | RSU Grant | Taysha Gene Therapies, Inc."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Stock Option Grant financial

"01/02/2024 | Stock Option Grant | Taysha Gene Therapies, Inc"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TSHA's Form 144 report show?

It reports a proposed sale of 200,000 shares by Sukumar Nagendran with a listed amount of $942,740. The filing includes the sale date 01/12/2026 and lists prior RSU and option grants with their grant dates.

Who is the selling party on the TSHA Form 144?

The selling party is listed as Sukumar Nagendran. The filing shows his address and the proposed sale quantity of 200,000 shares dated 01/12/2026 without further settlement details in the excerpt.

Does the Form 144 show other equity awards for TSHA insiders?

Yes. The excerpt lists earlier equity grants: 131,550 RSUs (01/02/2024), 49,429 RSUs (01/02/2025), and a 19,021 stock option grant (01/02/2024). No vesting or exercise details are provided here.

Has the proposed sale been completed according to the filing excerpt?

The excerpt records a proposed sale dated 01/12/2026 and an associated dollar amount of $942,740; it does not state whether the transaction was completed. Completion would appear in subsequent transaction reports or broker confirmations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/10/2026 - 04:11 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001665124
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Taysha Gene Therapies, Inc.
SEC File Number	001-39536
Address of Issuer	3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TEXAS 75247
Phone	(214) 612-0000
Name of Person for Whose Account the Securities are To Be Sold	Nagendran Sukumar
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue 4th Floor New York NY 10022	200000	926000.00	287000000	04/10/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/02/2024	RSU Grant	Taysha Gene Therapies, Inc.			131550	01/02/2024	N/A
Common	01/02/2025	RSU Grant	Taysha Gene Therapies, Inc.			49429	01/02/2025	N/A
Common	01/02/2024	Stock Option Grant	Taysha Gene Therapies, Inc			19021	01/02/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sukumar Nagendran 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247	Common	01/12/2026	200000	942740.00

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 6/11/2025 and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	04/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Sukumar Nagendran
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)